Sectoral Asset Management Inc. Increases Position in Illumina, Inc. (NASDAQ:ILMN)

Sectoral Asset Management Inc. lifted its stake in Illumina, Inc. (NASDAQ:ILMNFree Report) by 4.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 6,600 shares of the life sciences company’s stock after purchasing an additional 300 shares during the period. Sectoral Asset Management Inc.’s holdings in Illumina were worth $919,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in ILMN. Annis Gardner Whiting Capital Advisors LLC purchased a new position in Illumina in the third quarter valued at $30,000. VisionPoint Advisory Group LLC boosted its stake in shares of Illumina by 344.6% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock worth $34,000 after acquiring an additional 193 shares in the last quarter. Wetzel Investment Advisors Inc. acquired a new position in shares of Illumina during the 4th quarter worth approximately $37,000. Gradient Investments LLC raised its holdings in Illumina by 375.0% in the 4th quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock valued at $40,000 after acquiring an additional 225 shares during the last quarter. Finally, North Star Investment Management Corp. raised its holdings in Illumina by 183.0% in the 4th quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock valued at $42,000 after acquiring an additional 194 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on ILMN shares. OTR Global reaffirmed a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. Jefferies Financial Group started coverage on shares of Illumina in a research note on Monday, June 3rd. They set a “hold” rating and a $115.00 price objective on the stock. TD Cowen dropped their price target on shares of Illumina from $140.00 to $122.00 and set a “hold” rating on the stock in a research note on Thursday. Scotiabank decreased their price objective on shares of Illumina from $185.00 to $176.00 and set a “sector outperform” rating for the company in a report on Monday, May 6th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $253.00 price objective on shares of Illumina in a report on Tuesday, April 9th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $161.24.

Get Our Latest Report on Illumina

Illumina Stock Down 0.9 %

NASDAQ ILMN traded down $1.02 on Friday, hitting $113.70. 2,850,090 shares of the company were exchanged, compared to its average volume of 2,057,189. The stock has a fifty day moving average of $116.80 and a 200-day moving average of $126.94. The company has a market cap of $18.11 billion, a PE ratio of -13.95 and a beta of 1.20. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $212.49.

Illumina (NASDAQ:ILMNGet Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The firm’s quarterly revenue was down 1.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.08 earnings per share. As a group, analysts forecast that Illumina, Inc. will post 0.88 earnings per share for the current year.

About Illumina

(Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Featured Articles

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMNFree Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.